Document Detail


Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721.
MedLine Citation:
PMID:  11734190     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of the endothelin ET(A), (BQ-123) and endothelin ET(A/B) (PD161721) receptor antagonists were investigated on ischaemia-induced arrhythmias and on the maximum following frequency. The study was carried out in Langendorff perfused rat hearts subjected to coronary artery occlusion in which the severity of arrhythmias, coronary perfusion pressure and heart rate were measured. The % incidence of ischaemia-induced irreversible ventricular fibrillation (ventricular fibrillation) was reduced significantly from 58%, in control rat hearts, to 0% (at 10(-7) and 10(-6) M PD161721 and 10(-6) M BQ-123 P<0.05). Maximum following frequency was measured in guinea-pig isolated atria. In the presence of normal extracellular [K(+)], BQ-123 and PD161721, at 10(-6) M, significantly decreased the maximum following frequency from 9.0+/-0.7 to 7.2+/-0.4 and from 8.3+/-0.4 to 6.7+/-0.3 Hz, respectively (P<0.05). These effects were not potentiated by raising the extracellular [K(+)] with the exception of 10(-9) M PD161721. In contrast, lignocaine's ability to reduce the maximum following frequency was greater in elevated (e.g. at 1.7x10(-4) M from 8.4+/-0.3 to 2.5+/-0.6 Hz) than in normal [K(+)] (from 9.0+/-0.3 to 4.9+/-0.5 Hz). In conclusion, both BQ-123 and PD161721 had an anti-fibrillatory effect in isolated rat hearts that may be due, at least in part, to an ability to reduce the maximum following frequency. This latter effect is unlikely to be due to Na(+) channel blockade since it was not markedly potentiated by elevation of extracellular [K(+)].
Authors:
T R Crockett; G A Scott; N W McGowan; K A Kane; C L Wainwright
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of pharmacology     Volume:  432     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-12-05     Completed Date:  2002-02-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  71-7     Citation Subset:  IM    
Affiliation:
Department of Physiology and Pharmacology, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, 27 Taylor Street, G4 0NR, Scotland, Glasgow, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Arrhythmia Agents / pharmacology*
Arrhythmias, Cardiac / etiology,  physiopathology,  prevention & control
Atrial Function
Dioxins / pharmacology*
Dose-Response Relationship, Drug
Electrophysiology
Guinea Pigs
Heart / drug effects,  physiology
Heart Atria / drug effects
Heart Rate / drug effects
Lidocaine / pharmacology
Male
Muscle Contraction / drug effects
Myocardial Ischemia / complications
Peptides, Cyclic / pharmacology*
Perfusion
Pressure
Rats
Rats, Sprague-Dawley
Receptors, Endothelin / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Dioxins; 0/PD 161721; 0/Peptides, Cyclic; 0/Receptors, Endothelin; 136553-81-6/cyclo(Trp-Asp-Pro-Val-Leu); 137-58-6/Lidocaine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel marine-derived halogen-containing gramine analogues induce vasorelaxation in isolated rat aort...
Next Document:  Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis.